Latest IDT AUSTRALIA (ASX:IDT) News

IDT Australia reports a robust 20.3% increase in core revenue and a dramatic narrowing of EBITDA losses, signalling early success from its strategic realignment under new leadership.

IDT Australia Limited has reported a significant narrowing of its half-year loss to $1.3 million, driven by stable revenues and operational efficiencies. The pharmaceutical manufacturer highlights growth in key segments despite some timing setbacks.

IDT Australia announces a strategic realignment focusing on profitability and operational efficiency, reporting strong revenue growth from its three core verticals and securing $3.4 million in new contracts for FY26.

IDT Australia Limited reported a strong 40.6% increase in revenue to $19.86 million for FY25, driven by growth in advanced therapies and contract disbursements. However, the company’s net loss widened to $8.06 million as it transitions from its ‘Rebuild Strategy’ to a new phase focused on sustainable profitability.

IDT Australia announces the immediate resignation of CEO Paul McDonald, appointing Executive Chair Mark Simari to lead as the company reports a 40.6% revenue increase but a widening net loss for FY25.

IDT Australia has signed a memorandum with NASDAQ-listed Gelteq to establish a dedicated gel-based product manufacturing facility, marking a strategic expansion in pharmaceutical delivery technologies.

IDT Australia reports a robust 30% jump in quarterly revenue to $4.1 million, driven by strong contract wins and a $62 million pipeline of open proposals, signaling sustained growth in pharmaceutical manufacturing.

IDT Australia reports a near doubling of quarterly revenue to $5.3 million, driven by explosive growth in its Advanced Therapies segment, with first-half revenue expected to jump 82%.

IDT Australia has finalized a $20 million asset-based loan facility with ScotPac, replacing its previous $4.7 million NAB facility, to support its expanding sales pipeline and recent contract wins.